Try our beta test site
4 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND Pixantrone [TREATMENT] | Open Studies
Show Display Options
Rank Status Study
1 Recruiting GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Obinutuzumab and Pixantrone
2 Recruiting Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Condition: Malignant Lymphoma
Intervention: Drug: PREBEN
3 Recruiting Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Conditions: Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
4 Recruiting Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
Conditions: Lymphoma;   Solid Tumor (Excluding CNS)
Intervention: Drug: Pixantrone

Study has passed its completion date and status has not been verified in more than two years.